user

Efficacy of bi-weekly docetaxel in hormone-sensitive metastatic prostate cancer (mHSPC).

被引：0
|
作者：
Lombana Quinonez, Milton Alberto
Milena Torres, Ana
Gonzalez, Guido
机构：
[1] Ctr Integral Canc Clin Occidente, Cali, Colombia
[2] Nalt Med Solut, Cali, Colombia
[3] Clin Occidente, Cali, Colombia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17070
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and tolerability of docetaxel chemotherapy in 'real-world' patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Maw, May Tun Hla
    Malik, Laeeq
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 127 - 127
  • [2] Docetaxel for hormone-sensitive metastatic prostate cancer
    Baker, Holly
    LANCET ONCOLOGY, 2015, 16 (09): : E432 - E432
  • [3] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Merseburger, Axel S.
    Suttmann, Henrik
    AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
  • [4] Use of abiraterone for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Cathomas, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 130 - 130
  • [5] DISEASE BURDEN OF METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) IN CHINA
    Yu, M.
    Duan, X.
    Wang, J.
    Zhang, X. J.
    Yu, F.
    VALUE IN HEALTH, 2021, 24 : S39 - S40
  • [6] Recent developments in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Schwentner, Christian
    AKTUELLE UROLOGIE, 2022, 53 (01) : 31 - 36
  • [7] Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease
    Schoen, Martin W.
    Etzioni, Ruth Douglas
    Luo, Suhong
    Candelieri, Danielle
    Fedele, Nicholas
    Baxi, Priya
    Pickett, Carley
    Riekhof, Forest
    Ingram, Kara
    Karunanandaa, Krishny
    Govindan, Srinivas
    Cheranda, Nina
    Knoche, Eric Marshall
    Montgomery, Robert Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).
    Smith, Matthew Raymond
    Saad, Fred
    Hussain, Maha
    Sternberg, Cora N.
    Fizazi, Karim
    Yamada, Karin Sayuri
    Kappeler, Christian
    Kuss, Iris
    Tombal, Bertrand F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [9] Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm
    Weiner, Adam B.
    Nettey, Oluwarotimi S.
    Morgans, Alicia K.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (09)
  • [10] IDENTIFYING AND CHARACTERIZING METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) POPULATION IN FINLAND
    Ruotsalainen, J.
    Korhonen, M. J.
    Purmonen, T.
    Joutseno, J.
    Saavuori, N.
    VALUE IN HEALTH, 2023, 26 (12) : S535 - S535
12345